

ABSTRACT

- A pharmaceutical composition comprises, as a first active agent, $6\beta,7\beta;15\beta,16\beta$ -dimethylene-3-oxo- 17α -pregn-4-ene-21,17-carbolactone (drospirenone) in an amount
- 5 corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α -ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients.
- 10 In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing
- 15 ethinylestradiol alone.

007E80" 22245960